← Back to Screener
Tenax Therapeutics, Inc. (TENX)
Price$14.10
Favorite Metrics
Price vs S&P 500 (26W)84.95%
Price vs S&P 500 (4W)-8.44%
Market Capitalization$247.99M
All Metrics
Book Value / Share (Quarterly)$10.42
P/TBV (Annual)3.79x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.84
Price vs S&P 500 (YTD)14.40%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-10115.82%
EPS (TTM)$-1.34
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-1.34
EPS (Annual)$-1.34
ROI (Annual)-54.19%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-12872.94%
Cash / Share (Quarterly)$10.47
ROA (Last FY)-50.47%
Revenue Growth TTM (YoY)-82.93%
EBITD / Share (TTM)$-1.44
ROE (5Y Avg)-337.11%
Operating Margin (TTM)-10390.47%
Cash Flow / Share (Annual)$-3.84
P/B Ratio2.55x
P/B Ratio (Quarterly)0.78x
Net Income / Employee (Annual)$-4
EV / Revenue (TTM)3051.21x
Net Interest Coverage (TTM)-320.28x
ROA (TTM)-49.51%
EPS Incl Extra (Annual)$-1.34
Current Ratio (Annual)14.56x
Quick Ratio (Quarterly)13.78x
3-Month Avg Trading Volume0.34M
52-Week Price Return165.14%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$10164.00
P/S Ratio (Annual)5030.21x
Asset Turnover (Annual)0.00x
52-Week High$18.38
Operating Margin (5Y Avg)-10572.22%
EPS Excl Extra (Annual)$-1.34
Tangible BV CAGR (5Y)47.56%
26-Week Price Return93.70%
Quick Ratio (Annual)13.78x
13-Week Price Return-20.91%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.56x
Enterprise Value$150.425
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-55.21%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)-28563.49%
Cash / Share (Annual)$10.47
3-Month Return Std Dev104.29%
Gross Margin (5Y Avg)57.92%
Net Income / Employee (TTM)$-4
ROE (Last FY)-54.19%
Net Interest Coverage (Annual)-17.63x
EPS Basic Excl Extra (Annual)$-1.34
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.34
Receivables Turnover (Annual)0.00x
ROI (TTM)-51.83%
P/S Ratio (TTM)5030.21x
Pretax Margin (5Y Avg)-12872.94%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$17141.00
Price vs S&P 500 (52W)130.04%
Year-to-Date Return18.54%
5-Day Price Return-0.34%
EPS Normalized (Annual)$-1.34
ROA (5Y Avg)-201.92%
Net Profit Margin (Annual)-28563.49%
Month-to-Date Return-9.63%
Cash Flow / Share (TTM)$-0.49
EBITD / Share (Annual)$-1.44
Operating Margin (Annual)-30054.16%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-292.37%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.34
P/TBV (Quarterly)1.04x
P/B Ratio (Annual)0.78x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-10115.82%
Book Value / Share (Annual)$10.42
Price vs S&P 500 (13W)-23.77%
Beta1.12x
Revenue / Share (TTM)$0.00
ROE (TTM)-51.83%
52-Week Low$4.63
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.36
4.36
4.36
4.33
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TENXTenax Therapeutics, Inc. | 5030.21x | -82.93% | 100.00% | — | $14.10 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Tenax Therapeutics is a specialty pharmaceutical company focused on cardiovascular and pulmonary diseases with high unmet medical needs. The company's lead asset is levosimendan (North American rights), currently in Phase 2 development for pulmonary hypertension associated with heart failure with preserved ejection fraction.